Journal article
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
P Rescigno, D Dolling, V Conteduca, M Rediti, D Bianchini, C Lolli, M Ong, H Li, AG Omlin, S Schmid, O Caffo, A Zivi, CJ Pezaro, C Morley, D Olmos, N Romero-Laorden, E Castro, MI Saez, N Mehra, S Smeenk Show all
European Urology Oncology | ELSEVIER | Published : 2020
Open access
Abstract
Background: Declines in prostate-specific antigen (PSA) levels at 12 wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4 wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study. Objective: To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. Design, setting, and participants: This was a retrospective multicentre analysis. Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 December 2017 in 13 cancer centres worldwide, and had PSA levels assessed a..
View full abstract